Mesa Laboratories Inc: Form 10-Q for the period ended Sep 30, 2015
Filed with the SEC on Nov 4, 2015 and accepted by EDGAR at Nov 4, 2015, 08:01 ET.
Management's discussion and analysis
As filed, 32,664 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Forward Looking Statements
This report contains information that may constitute "forward-looking statements.” Generally, the words "believe," "expect," "project," “anticipate,” "estimate," "intend," "will" and similar expressions identify forward-looking statements, which generally are not historical in nature. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future — including statements relating to revenue growth and statements expressing general views about future operating results — are forward-looking statements. Management believes that these forward-looking statements are reasonable as and when made. However, caution should be taken not to place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to those described in Part II, "Item 1A. Risk Factors" and elsewhere in this report and in our Annual Report on Form 10-K for the year ended March 31, 2015, and those described from time to time in our subsequent reports filed with the Securities and Exchange Commission.
General Discussion
We pursue a strategy of focusing primarily on quality control products and services, which are sold into niche markets that are driven by regulatory requirements. We prefer markets that have limited competition where we can establish a commanding presence and achieve high gross margins. We are organized into four divisions across eight physical locations. Our Instruments Division designs, manufactures and markets quality control instruments and disposable products utilized in connection with the healthcare, pharmaceutical, food and beverage, medical device, industrial hygiene, environmental air sampling and semiconductor industries. Our Biological Indicators Division manufactures and markets biological indicators and distributes chemical indicators used to assess the effectiveness of sterilization processes, including steam, hydrogen peroxide, ethylene oxide and radiation, in the hospital, dental, medical device and pharmaceutical industries. Our Continuous Monitoring Division designs, develops and markets systems which are used to monitor various environmental parameters such as temperature, humidity and differential pressure to ensure that critical storage and processing conditions are maintained in hospitals, pharmaceutical and medical device manufacturers, blood banks, pharmacies and a number of other laboratory and industrial environments. Our Cold Chain Division provides parameter monitoring of products in a cold chain, consulting services such as compliance monitoring, packaging development and validation or mapping of transport and storage containers, and thermal packaging products such as coolers, boxes, insulation materials and phase-change products to control temperature during transport.
Our revenues come from two main sources – product sales and services. Product sales are dependent on several factors, including general economic conditions, both domestic and international, customer capital spending trends, competition, introduction of new products and acquisitions. Biological indicator and cold chain packaging products are disposable and are used on a routine basis for quality control, thus product sales are less sensitive to general economic conditions. Instrument products, cold chain services and continuous monitoring systems have a longer life, and their purchase by our customers is somewhat discretionary, so sales are more sensitive to general economic conditions. Service demand is driven by our customers’ quality control and regulatory environments, some of which require periodic repair and recalibration or certification of our instrument products and continuous monitoring systems. We typically evaluate costs and pricing annually. Our policy is to price our products and systems competitively and, where possible, we try to pass along cost increases in order to maintain our margins.
Gross profit is affected by our product mix, manufacturing efficiencies and price competition. Historically, as we have integrated our acquisitions and taken advantage of manufacturing efficiencies, our gross margins for some of the products have improved. There are, however, differences in gross margins between different product lines, and ultimately the mix of sales will continue to impact our overall gross margin.
Selling expense is driven primarily by labor costs, including salaries and commissions. Accordingly, it may vary with sales levels. Labor costs and amortization of intangible assets drive the substantial majority of general and administrative expense. Research and development expense is predominantly comprised of labor costs and third party consultants.
Year Ending March 31, 2016 Acquisitions
During the year ending March 31, 2016, we completed the following eight acquisitions (the “2016 Acquisitions”):
In October 2015, we completed six business combinations (the “October 2015 European BI Distributor Acquisitions”) whereby we acquired substantially all of the assets (other than cash and accounts receivable) and certain liabilities of BIOLOGIK S.R.L., VWR International PBI S.R.L., Cruinn Diagnostics Ltd., Mecolab AG, Miclev Medical Products AB and Tiselab S.L.’s business segment associated with the distribution of our biological indicator products.
In August 2015, we completed a business combination (the “North Bay Acquisition”) whereby we acquired substantially all of the assets (other than certain fixed assets) and certain liabilities of the dental sterilizer testing business of North Bay Bioscience, LLC (“North Bay”).
In July 2015, we completed a business combination (the “Infitrak Acquisition”) whereby we acquired all of the common stock of 2396081 Ontario Inc. and its wholly owned operating subsidiary, Infitrak Inc. (collectively “Infitrak”), a company whose business provides consulting, packaging and measuring solutions for cold chain applications.
Year Ended March 31, 2015 Acquisitions
During the year ended March 31, 2015, we completed the following six acquisitions (the “2015 Acquisitions”):
In March 2015, we completed a business combination (the “Früh Acquisition”) whereby we acquired substantially all of the assets (other than cash and accounts receivable) and certain liabilities of Dr. Früh Control GmbH’s (“Fruh”) business segment associated with the distribution of our biological indicator products.
In February 2015, we completed a business combination (the “Cherwell Acquisition”) whereby we acquired substantially all of the assets (other than cash and accounts receivable) and certain liabilities of Cherwell Laboratories Limited’s (“Cherwell”), business segment associated with the distribution of our biological indicator products.
In October 2014, we completed a business combination (the “ATI Acquisition”) whereby we acquired substantially all of the assets (other than cash and accounts receivable) and certain liabilities of ATI Atlas Limited (“ATI”), a distributor of our biological indicator products.
In October 2014, we completed a business combination (the “PCD Acquisition”) with PCD-Process Challenge Devices, LLC (“PCD”) whereby we acquired substantially all of the assets (other than cash and accounts receivable) and certain liabilities of PCD’s business segment associated with the sale of process challenge devices (“PCD’s”), which are used for quality control purposes in the field of ethylene oxide sterilization of medical devices.
In April 2014, we completed a business combination (the “BGI Acquisition”) whereby we acquired substantially all of the assets (other than cash and accounts receivable) and certain liabilities of BGI, Incorporated and BGI Instruments, Inc., (collectively “BGI”), businesses focused on the sale of equipment used primarily for particulate air sampling.
In April 2014, we completed a business combination (the “Amilabo Acquisition”) whereby we acquired all of the common stock of Amilabo SAS (“Amilabo”), a distributor of our biological indicator products.
General Trends and Outlook
Our strategic objectives include growth both organically and through further acquisitions. During the year ended March 31, 2015, we continued to build our infrastructure to prepare for future growth, including the addition of key personnel to our operations, sales and marketing, research and development, and finance teams. We also invested in upgrading our information systems and intend to continue doing so.
The markets for our biological indicators and cold chain packaging products remain strong, as the disposable nature of these products makes them less sensitive to general economic conditions. The worldwide market for biological indicators is growing as more countries focus on verifying the effectiveness of sterilization processes.
In general, our instruments products, cold chain services and our continuous monitoring systems are impacted more by general economic conditions than our biological indicator and cold chain packaging products. As a result, uncertainty about global economic conditions may cause businesses to postpone spending in response to tighter credit, unemployment, negative financial news and/or declines in income or asset values. Worldwide and regional economic conditions could also reduce the demand for our products and services, as our customers reduce or delay capital equipment and other types of purchases. However demand for our instruments products, cold chain services and continuous monitoring systems remains strong and we strive to continue to grow revenues going forward.
We are working on several research and development projects that, if completed, may result in new products for both existing customers and new markets. We are hopeful that all of our divisions will have new products available for sale in the coming year.
Results of Operations
The following table sets forth, for the periods indicated, condensed consolidated statements of income data. The table and the discussion below should be read in conjunction with the accompanying condensed consolidated financial statements and the notes thereto appearing elsewhere in this report (in thousands, except percent data):
| Three Months Ended September 30, 2015 | 2014 | Change | Percent Change | |
|---|---|---|---|---|
| Revenues | $21,776 | $18,540 | $3,236 | 17% |
| Cost of revenues | 8,709 | 7,417 | 1,292 | 17% |
| Gross profit | $13,067 | $11,123 | $1,944 | 17% |
| Gross profit margin | 60% | 60% | --% | |
| Operating expenses | ||||
| Selling | $2,288 | $1,342 | $946 | 70% |
| General and administrative | 6,782 | 4,005 | 2,777 | 69% |
| Research and development | 991 | 876 | 115 | 13% |
| $10,061 | $6,223 | $3,838 | 62% | |
| Operating income | $3,006 | $4,900 | $(1,894) | (39)% |
| Net income | 1,752 | 3,060 | (1,308) | (43)% |
| Net profit margin | 8% | 17% | (9)% |
| Six Months Ended September 30, 2015 | 2014 | Change | Percent Change | |
|---|---|---|---|---|
| Revenues | $39,934 | $34,940 | $4,994 | 14% |
| Cost of revenues | 15,726 | 14,112 | 1,614 | 11% |
| Gross profit | $24,208 | $20,828 | $3,380 | 16% |
| Gross profit margin | 61% | 60% | 1% | |
| Operating expenses | ||||
| Selling | $4,087 | $3,405 | $682 | 20% |
| General and administrative | 11,519 | 7,841 | 3,678 | 47% |
| Research and development | 1,954 | 1,627 | 327 | 20% |
| $17,560 | $12,873 | $4,687 | 36% | |
| Operating income | $6,648 | $7,955 | $(1,307) | (16)% |
| Net income | 4,058 | 4,941 | (883) | (18)% |
| Net profit margin | 10% | 14% | (4)% |
Page 17
Revenues
The following table summarizes our revenues by source (in thousands, except percent data):
| Three Months Ended September 30, 2015 | 2014 | Change | Percent Change | |
|---|---|---|---|---|
| Biological Indicators | $8,482 | $6,441 | $2,041 | 32% |
| Instruments | 9,228 | 9,065 | 163 | 2% |
| Continuous Monitoring | 2,226 | 3,034 | (808) | (27)% |
| Cold Chain | 1,840 | -- | 1,840 | 100% |
| Total | $21,776 | $18,540 | $3,236 | 17% |
| Six Months Ended September 30, 2015 | 2014 | Change | Percent Change | |
|---|---|---|---|---|
| Biological Indicators | $15,718 | $12,858 | $2,860 | 22% |
| Instruments | 17,559 | 16,750 | 809 | 5% |
| Continuous Monitoring | 4,817 | 5,332 | (515) | (10)% |
| Cold Chain | 1,840 | -- | 1,840 | 100% |
| Total | $39,934 | $34,940 | $4,994 | 14% |
Three and six months ended September 30, 2015 versus September 30, 2014
Biological Indicators revenues for the three and six months ended September 30, 2015 increased as a result of the ATI, PCD, Früh, Cherwell and North Bay Acquisitions and organic growth of five and two percent, respectively which was achieved through existing customers, expansion into new markets and price increases.
Instruments revenues for the three months ended September 30, 2015 increased as a result of organic growth of two percent in our existing product lines which was achieved primarily through existing and new customers. Instruments revenues for the six months ended September 30, 2015 increased as a result of the timing of the BGI Acquisition and organic growth of four percent in our existing product lines which was achieved primarily through existing and new customers.
Continuous Monitoring revenues for the three and six months ended September 30, 2015 decreased primarily due to strong revenues in the second quarter in the prior year as a result of the timing of certain system installations. On a go forward basis, we anticipate the run rate for our Continuous Monitoring segment to approximate $2,500,000 per quarter over the next few quarters.
Gross Profit
The following summarizes our gross profit by segment (in thousands, except percent data):
| Three Months Ended September 30, 2015 | 2014 | Change | Percent Change | |
|---|---|---|---|---|
| Biological Indicators | $5,539 | $4,051 | $1,488 | 37% |
| Gross profit margin | 65% | 63% | 2% | |
| Instruments | 5,705 | 5,455 | 250 | 5% |
| Gross profit margin | 62% | 60% | 2% | |
| Continuous Monitoring | 955 | 1,617 | (662) | (41)% |
| Gross profit margin | 43% | 53% | (10)% | |
| Cold Chain | 868 | -- | 868 | 100% |
| Gross profit margin | 47% | --% | 47% | |
| Total gross profit | $13,067 | $11,123 | $1,944 | 17% |
| Gross profit margin | 60% | 60% | --% |
Page 18
| Six Months Ended September 30, 2015 | 2014 | Change | Percent Change | |
|---|---|---|---|---|
| Biological Indicators | $10,288 | $7,835 | $2,453 | 31% |
| Gross profit margin | 65% | 61% | 4% | |
| Instruments | 11,060 | 10,382 | 678 | 7% |
| Gross profit margin | 63% | 62% | 1% | |
| Continuous Monitoring | 1,992 | 2,611 | (619) | (24)% |
| Gross profit margin | 41% | 49% | (8)% | |
| Cold Chain | 868 | -- | 868 | 100% |
| Gross profit margin | 47% | --% | 47% | |
| Total gross profit | $24,208 | $20,828 | $3,380 | 16% |
| Gross profit margin | 61% | 60% | 1% |
Three and six months ended September 30, 2015 versus September 30, 2014
Biological Indicators gross profit margin percentage for the three and six months ended September 30, 2015 increased primarily as a result of the ATI, PCD, Früh and Cherwell Acquisitions, price increases and volume-based efficiencies associated with revenues growth.
Instruments gross profit margin percentage for the three and six months ended September 30, 2015 increased primarily as a result of changes in product and service mix.
Continuous Monitoring gross profit margin decreased for the three and six months ended September 30, 2015 primarily as a result of a change in our product service mix. Additionally, the gross profit margin percentage for the three months ended September 30, 2014 was positively impacted by the timing of revenues recognized in that period (see revenues). We have made substantial progress on our integration activities associated with this segment and we are now also focused on cost reduction initiatives to stream line the operations and increase profitability. We saw some impact of these initiatives during the three months ended September 30, 2015 as gross profit margin percentage increased to 43 percent as compared to 40 percent for the three months ended June 30, 2015. We are hopeful that we will continue to improve the gross margin percentage in the future but it is unclear as to how much improvement we will be able to obtain.
We expect that our Cold Chain gross profit margin percentage will continue to be lower than the historical results of our other segments due to the nature of the cold chain products. This lower gross profit percentage however is offset by lower operating expenses (as a percentage of revenues) and as a result, we expect that operating income margins for our Cold Chain segment to be similar to those of our other segments.
Operating Expenses
Operating expenses for the three and six months ended September 30, 2015 increased as compared to the prior year as follows (in thousands):
| Increase (Decrease) Three Months Ended September 30, 2015 | Six Months Ended September 30, 2015 | |
|---|---|---|
| Selling | $946 | $682 |
| General and administrative | ||
| ERP system upgrade | 223 | 291 |
| Amortization | 320 | 640 |
| Personnel costs | 440 | 725 |
| Acquisition costs | 40 | -- |
| Litigation settlement | 1,709 | 1,709 |
| Other, net | 45 | 313 |
| 2,777 | 3,678 | |
| Research and development | 115 | 327 |
| Operating expenses | $3,838 | $4,687 |
Selling
Three and six months ended September 30, 2015 versus September 30, 2014
Selling expense for the three months ended September 30, 2015 increased primarily due to the PCD, Infitrak and North Bay Acquisitions, an increase in our reserve for bad debts of $175,000 associated with the collectability of older accounts receivable (as compared to $200,000 of contra expense during the three months ended September 30, 2014 due to the collection of certain accounts receivable that had been previously reserved) along with minor fluctuations due to the timing of certain expenses. As a percentage of revenues, selling expense increased to 11 percent as compared to seven percent in the prior period.
Selling expense for the six months ended September 30, 2015 increased primarily due to the PCD, Infitrak and North Bay Acquisitions, an increase in our reserve for bad debts of $250,000 associated with the collectability of older accounts receivable (as compared to $5,000 for the six months ended September 30, 2014) along with negligible increases from other product lines. As a percentage of revenues, selling expense was 10 percent for both the six months ended September 30, 2015 and 2014.
Historically selling expense approximates 10 to 12 percent of revenues.
General and Administrative
Three and six months ended September 30, 2015 versus September 30, 2014
General and administrative expenses for the three and six months ended September 30, 2015 increased primarily due increased amortization and personnel costs resulting from the PCD, Infitrak, and North Bay Acquisitions, increased spending on our ERP system upgrade and the Amato Settlement.
Research and Development
Three and six months ended September 30, 2015 versus September 30, 2014
Research and development expenses for the three and six months ended September 30, 2015 increased as a result of the addition of several new engineers to support existing and acquired businesses.
Net Income
Net income for the three and six months ended September 30, 2015 was significantly impacted by the $1,709,000 Amato Settlement. Our income tax rate varies based upon many factors but in general, we anticipate that on a go forward basis, our effective tax rate will approximate 35 to 37 percent. Otherwise, net income for the six months ended September 30, 2015 varied with the changes in revenues, gross profit and operating expenses (which includes $2,760,000 of non-cash amortization of intangible assets).
Liquidity and Capital Resources
Our sources of liquidity may include cash generated from operations, working capital, capacity under our Credit Facility and potential equity and debt offerings. We believe that cash generated from these sources will be sufficient to meet our short-term and long-term needs. Our more significant uses of resources include quarterly dividends to shareholders, payment of debt obligations, long-term capital equipment expenditures and potential acquisitions.
Due to continued organic and acquisition related growth, we have outgrown the capacity of our current building in Bozeman, Montana and as a result, we are building a new facility in the same general area. Construction began in July 2015 and we are hopeful that the building will be completed no later than September 30, 2016. During our year ended March 31, 2015 we acquired the related land for $741,000 and have spent $3,500,000 during the six months ended September 30, 2015, which is included in property, plant and equipment, net on the accompanying condensed consolidated balance sheets. We anticipate that the total cost of the new facility will be approximately $14,750,000. Following the relocation from our current Bozeman building into the new facility, we expect to be able to sell the current facility for $2,000,000 - $3,000,000 to partially offset the cost of the new building.
We are currently implementing a new ERP system which has required a significant amount of cash. We incurred $475,000 and $993,000, respectively of expense associated with this project for the six months ended September 30, 2015 and the year ended March 31, 2015. We went live on our new ERP system on October 1, 2015 and we anticipate that we will incur up to an additional $500,000 for activities necessary for related post go-live support and additional projects and enhancements. In addition, we may incur additional costs associated with software system upgrades.
Working capital is the amount by which current assets exceed current liabilities. We had working capital of $11,140,000 and $14,965,000, respectively, at September 30, 2015 and March 31, 2015.
In February 2012, we entered into a three year agreement (the “Credit Facility”) for a $20,000,000 revolving line of credit (“Line of Credit”) and up to $1,000,000 of letters of credit. Funds from the Credit Facility were used for general working capital and corporate needs, retiring existing debt, or to support acquisitions and capital expenditures.
In April 2014, the Credit Facility was amended to include a $15,000,000 term loan (the “Initial Term Loan”) and to extend the maturity date of the Credit Facility to June 30, 2017.
On July 1, 2015, we further amended our Credit Facility to extend the maturity date to June 30, 2020, increase the Line of Credit to $50,000,000 and establish a new $20,000,000 term loan (the “Term Loan”). The majority of the proceeds from the Term Loan were used to pay down the remaining $12,000,000 balance of the Initial Term Loan.
Under the Line of Credit, indebtedness bears interest at either: (1) LIBOR, as defined, plus an applicable margin ranging from 1.5% to 2.25%; or (2) the bank’s commercial bank floating rate (“CBFR”), which is the bank’s prime rate adjusted down by 0.5%.
The Term Loan bears interest at LIBOR, as defined, plus an applicable margin ranging from 1.5% to 2.25% and requires 20 quarterly principal payments (the first due date was July 15, 2015) in the amount of $750,000 with the remaining balance of principal and accrued interest due on June 30, 2020.
The Credit Facility is secured by all of our assets and requires us to maintain a ratio of funded debt to our trailing four quarters of EBIDTA, as defined, of 3.25 to 1.0 through March 31, 2016 and 3.0 to 1.0 thereafter, and a minimum fixed charge coverage ratio of 1.35 to 1.0. We were in compliance with the required covenants at September 30, 2015.
As of October 31, 2015, we had $48,000,000 in outstanding indebtedness and unused capacity under our Credit Facility of $20,500,000.
In April 2015, the SEC declared effective our Universal Shelf Registration Statement which allows us to sell, in one or more public offerings, common stock or warrants, or any combination of such securities for proceeds in an aggregate amount of up to $130,000,000. The terms of any offering, including the type of securities involved, would be established at the time of sale. We have no immediate plans to issue securities under this registration statement.
We routinely evaluate opportunities for strategic acquisitions. Future material acquisitions may require that we obtain additional capital, assume third party debt or incur other long-term obligations. We believe that we have the option to utilize both equity and debt instruments as vehicles for the long-term financing of our investment activities and acquisitions.
On November 7, 2005, our Board of Directors authorized a program to repurchase up to 300,000 shares of our outstanding common stock. Under the plan, the shares may be purchased from time to time in the open market at prevailing prices or in negotiated transactions off the market. Shares purchased will be canceled and repurchases will be made with existing cash reserves. We do not maintain a set policy or schedule for our buyback program. We have purchased 162,486 shares of common stock under this program from inception through September 30, 2015.
We have been paying regular quarterly dividends since 2003. Dividends per share paid by quarter were as follows:
| Year Ending March 31, 2016 | 2015 | |
|---|---|---|
| First quarter | $0.16 | $0.15 |
| Second quarter | 0.16 | 0.15 |
| Third quarter | -- | 0.16 |
| Fourth quarter | -- | 0.16 |
In October 2015, our Board of Directors declared a quarterly cash dividend of $0.16 per share of common stock, payable on December 15, 2015, to shareholders of record at the close of business on November 30, 2015.
Cash Flows
Our cash flows from operating, investing and financing activities were as follows (in thousands):
| Six Months Ended September 30, 2015 | 2014 | |
|---|---|---|
| Net cash provided by operating activities | $8,962 | $3,744 |
| Net cash used in investing activities | (25,722) | (14,725) |
| Net cash provided by financing activities | 20,202 | 9,063 |
Net cash provided by operating activities for the six months ended September 30, 2015 increased primarily due to the efficient management of working capital.
Net cash used in investing activities for the six months ended September 30, 2015 resulted primarily from the $18,926,000 Infitrak and $11,322,000 North Bay Acquisitions and the purchase of $5,035,000 of property, plant and equipment. Net cash used in investing activities for the six months ended September 30, 2014 resulted primarily from the $10,268,000 BGI Acquisition and the purchase of $908,000 of property, plant and equipment.
Net cash provided by financing activities for the six months ended September 30, 2015 resulted from borrowings under our Credit Facility of $22,500,000 and proceeds from the exercise of stock options of $846,000, partially offset by the repayment of debt of $2,000,000 and the payment of dividends of $1,144,000. Net cash used in financing activities for the six months ended September 30, 2014 resulted from borrowings under our Line of Credit of $18,000,000 and proceeds from the exercise of stock options of $865,000, partially offset by the repayment of debt of $8,750,000 and the payment of dividends of $1,052,000.
At September 30, 2015, we had contractual obligations for open purchase orders of approximately $3,400,000 for routine purchases of supplies and inventory, which are payable in less than one year.
Under the terms of the PCD Agreement, we are required to pay contingent consideration if the cumulative revenues for our process challenge device business for the three years subsequent to the acquisition meet certain levels. The potential consideration payable ranges from $0 to $1,500,000 and is based upon a sliding scale of three-year cumulative revenues between $9,900,000 and $12,600,000. Based upon both historical and projected growth rates, we recorded $300,000 of contingent consideration payable which represented our best estimate of the amount that will ultimately be paid. The contingent consideration is payable in our quarter ending December 31, 2015 (based upon the current run rate projected over the entire three-year contingent consideration period) and is subject to modification at the end of the earn-out period based upon the actual revenues earned over the contingent consideration period. Any changes to the contingent consideration ultimately paid will result in additional income or expense in our condensed consolidated statements of income. We will continue to monitor the results of our process challenge device business and we will adjust the contingent liability on a go forward basis, based on then current information.
Under the terms of the Infitrak Agreement, we are required to pay contingent consideration if the gross profit (as defined in the Earn-Out Agreement) for our cold chain business for the two years subsequent to the acquisition meets certain levels. The potential consideration payable ranges from $0 to $15,000,000 CDN (approximately $11,500,000) and is based upon a sliding scale of growth in gross profit (as defined in the Earn-Out Agreement) for year one and year two of 30 to 70 percent and 15 to 75 percent, respectively. Based upon both historical and projected growth rates, we recorded $9,541,000 of contingent consideration payable which represents our best estimate of the amount that will ultimately be paid. After the finalization of our purchase accounting, any changes to the contingent consideration ultimately paid will result in additional income or expense in our condensed consolidated statements of income. We will continue to monitor the results of our cold chain business and we will adjust the contingent liability on a go forward basis, based on then current information. The contingent consideration is payable in two annual installments beginning in the second quarter of our year ending March 31, 2017.
In October 2015, we entered into the Amato Settlement whereby we paid Amato $3,165,000. In exchange, Amato agreed to dismiss the complaint, release Mesa of any and all claims by Amega and Amato, and relieve us of any future payment obligation under the Amega Earn-Out. Insurance covered $415,000 of the settlement payment while we had $1,041,000 accrued on our condensed consolidated balance sheet remaining from the original hold back and contingent consideration payable. The remaining $1,709,000 was recorded as general and administrative expense in the accompanying condensed consolidated statements of income for the three and six months ended September 30, 2015.
Critical Accounting Estimates
Our condensed consolidated financial statements and accompanying notes have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires management to make estimates, judgments and assumptions that affect reported amounts of assets, liabilities, revenues and expenses. We continually evaluate the accounting policies and estimates used to prepare the condensed consolidated financial statements. The estimates are based on historical experience and assumptions believed to be reasonable under current facts and circumstances. Actual amounts and results could differ from these estimates made by management. Certain accounting policies that require significant management estimates and are deemed critical to our results of operations or financial position are discussed in our Annual Report on Form 10-K for the year ended March 31, 2015 in the Critical Accounting Policies and Estimates section of “Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations.”
Controls and procedures
As filed, 2,892 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) that are designed to reasonably ensure that information required to be disclosed by us in the reports we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and that such information is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management evaluated, with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of our disclosure controls and procedures as of September 30, 2015. Based on that evaluation, our management concluded that our disclosure controls and procedures were effective at September 30, 2015.
Our management, including our Chief Executive Officer and Chief Financial Officer, is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with generally accepted accounting principles in the United States. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance of achieving their control objectives. Management evaluated the effectiveness of our internal control over financial reporting based on the framework in “Internal Control – Integrated Framework” issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in 2013.
Our management evaluated, with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of our internal control over financial reporting as of September 30, 2015. Based on that evaluation, our management concluded that our internal control over financial reporting was effective at September 30, 2015. As allowed, this evaluation excludes the operations of acquired entities during the six months ended September 30, 2015 due to the timing of the acquisitions.
Changes in Internal Control Over Financial Reporting
There were no significant changes in our internal control over financial reporting that occurred during the six months ended September 30, 2015, that have materially affected, or are reasonably likely to materially affect our internal control over financial reporting.
Risk factors
As filed, 439 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
We are affected by risks specific to us as well as factors that affect all businesses operating in a global market. The significant factors known to us that could materially adversely affect our business, financial condition or operating results are described in our Annual Report on Form 10-K for the year ended March 31, 2015, under the heading “Part I – Item 1A. Risk Factors.” There have been no material changes to those risk factors.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2015-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 6 months2015-04-01 to 2015-09-30 | $39.9m | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months2015-07-01 to 2015-09-30 | $8.7m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2015-04-01 to 2015-09-30 | $15.7m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2015-07-01 to 2015-09-30 | $13.1m | us-gaap:GrossProfit |
| Gross profit | 6 months2015-04-01 to 2015-09-30 | $24.2m | us-gaap:GrossProfit |
| Research and development | 3 months2015-07-01 to 2015-09-30 | $991.0k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2015-04-01 to 2015-09-30 | $2.0m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2015-07-01 to 2015-09-30 | $3.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2015-04-01 to 2015-09-30 | $6.6m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2015-07-01 to 2015-09-30 | $1.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2015-04-01 to 2015-09-30 | $2.3m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2015-07-01 to 2015-09-30 | $1.8m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Net income | 6 months2015-04-01 to 2015-09-30 | $4.1m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Diluted EPS | 3 months2015-07-01 to 2015-09-30 | $0.47 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2015-04-01 to 2015-09-30 | $1.09 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2015-07-01 to 2015-09-30 | $0.49 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2015-04-01 to 2015-09-30 | $1.13 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2015-07-01 to 2015-09-30 | 3,742,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2015-04-01 to 2015-09-30 | 3,715,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2015-04-01 to 2015-09-30 | $9.0m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Dividends paid | 6 months2015-04-01 to 2015-09-30 | $1.1m | us-gaap:PaymentsOfDividends |
| Cash and equivalents | At period end2015-09-30 | $5.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2015-09-30 | $35.0m | us-gaap:AssetsCurrent |
| Total assets | At period end2015-09-30 | $155.9m | us-gaap:Assets |
| Current liabilities | At period end2015-09-30 | $23.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2015-09-30 | $76.9m | us-gaap:Liabilities |
| Long-term debt | At period end2015-09-30 | $43.8m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2015-09-30 | $3.0m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2015-09-30 | $78.9m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001437749-15-019531. Last ingested by Listed: Nov 13, 2026, 07:45 ET. Listed shows no prices and gives no investment advice.